Compositions and Methods for Safe Treatment of Rhinitis
AssigneeRevance Therapeutics, Inc.
InventorsCurtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
Life of this patent
Estimating the term…
Abstract
Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.
Claims22
A method for treating rhinitis, the method comprising
- intranasally administering a therapeutically effective amount of a topical botulinum toxin composition to a patient in need of treatment;
- wherein said topical botulinum toxin composition comprises
- a purified 150 kDa botulinum neurotoxin isolated from botulinum toxin type A;
- a carrier molecule comprising a positively charged backbone with positively charged efficiency groups attached thereto;
- and
- a viscosity modifier in the form of a gel or a solution that forms a gel upon an increase in temperature;
- wherein the positively charged backbone comprises a polypeptide;
- and
- a pharmaceutically acceptable diluent;
- wherein said intranasal administration provides a dose of the purified botulinum neurotoxin of 250 U to 12,500 U to said patient.
2-4. (canceled)
18-22. (canceled)
A method for treating rhinitis, the method comprising
- intranasally administering a therapeutically effective amount of a topical botulinum toxin composition to a patient in need of treatment;
- wherein said topical botulinum toxin composition comprises
- a purified 150 kDa botulinum neurotoxin isolated from botulinum toxin type A;
- a carrier molecule comprising the amino acid sequence RKKRRQRRRG-(K)15-GRKKRRQRRR;
- and
- poloxamer 407.
A method for treating rhinitis, the method comprising
- intranasally administering a therapeutically effective amount of a topical botulinum toxin composition to a patient in need of treatment;
- wherein said topical botulinum toxin composition comprises
- a purified 150 kDa botulinum neurotoxin isolated from botulinum toxin type A;
- a carrier molecule comprising the amino acid sequence RKKRRQRRRG-(K)15-GRKKRRQRRR;
- and
- wherein said intranasal administration provides a dose of the purified botulinum neurotoxin of 250 U to 12,500 U to said patient.
Dependencies are inferred from the claim text.